Trial Profile
2 Cycles Rituximab Compared With Standard Regimen in Management of ITP
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 18 Apr 2016 Status changed from recruiting to withdrawn prior to enrolment as eligible patient was enrolled.
- 09 Jul 2014 New trial record